ClinicalTrials.gg
RecruitingNCT06340230Updated Dec 4, 2024

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

A Phase 2 interventional study of SHR-A1811 Injection + Adebrelimab Injection and SHR-A1811 Injection + Adebrelimab Injection in HR Positive/HER2 Low Breast Cancer, sponsored by Shengjing Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Shengjing Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing trastuzumab rezetecan in Breast Neoplasms — 46 open to participants now, 52 under way, 10 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
31st of 53
93 · median 111
Started
2024
with 4 others
Phase 2
34 of 53
34 open now
Primary completion
2026-02
later than 7 of 51 live
Registered
14th of 53
by date
Lead sponsor
2 of 53
Shengjing Hospital

Among the 53 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 31st largest by planned enrollment, is one of 5 that started in 2024, is one of 34 in phase 2, reaches primary completion later than 7 of the 51 other live ones, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

46 of the 53 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III HR Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles.

03

Conditions studied

  • HR Positive/HER2 Low Breast Cancer

Browse trials for

Keywords

  • SHR-A1811
  • Adebrelimab
  • Neoadjuvant
  • HR Positive/HER2 Low Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged ≥ 18 but ≤ 75 years
  2. confirmed to be HR+/-Low invasive breast cancer
  3. Treatment-naive patients with stage II-III
  4. (ECOG) score is 0 or 1
  5. Good level of organ function
  6. Subjects must participate voluntarily, sign the form, have good compliance, and cooperate with follow-up visits

Exclusion criteria

Exclusion Criteria:

  1. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)
  2. Received any other anti-tumor therapy at the same time
  3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer
  4. Stage IV breast cancer
  5. Not confirmed by histopathology
  6. With a history of any in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer
  7. Participated in other drug clinical trials within 4 weeks before enrollment
  8. Known allergic history of the drug components of this protocol
  9. History of immunodeficiency
  10. cardiovascular diseases
  11. Known or suspected interstitial lung disease
  12. Active hepatitis and liver cirrhosis
  13. Known hereditary or acquired bleeding thrombotic tendency
  14. History of neurological or psychiatric disorders
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Arm 1 (PD-L1 Positive) SHR-A1811 Injection + Adebrelimab Injection

    SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

    Drug: SHR-A1811 Injection + Adebrelimab Injection

  • Experimental
    Arm 2 (PD-L1 Negative) SHR-A1811 Injection + Adebrelimab Injection

    SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

    Drug: SHR-A1811 Injection + Adebrelimab Injection

  • Experimental
    Arm 3 SHR-A1811 Injection

    SHR-A1811 Injection Drug: SHR-A1811 Injection

    Drug: SHR-A1811 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Total pathological complete response (tpCR: ypT0-is/ypN0)

    Time frame: At the time of surgery

Secondary outcomes

  1. Breast pathological complete response (bpCR:ypT0-is)

    Time frame: At the time of surgery

  2. Residual cancer burden (RCB)

    Time frame: At the time of surgery

  3. Best overall response rate (BORR)

    Time frame: During 18 weeks of the neoadjuvant treatment

  4. Overall survival (OS)

    Time frame: 5 years

  5. Disease-free survival (DFS)

    Time frame: 5 years

  6. Event-free survival (EFS)

    Time frame: 5 years

  7. Health-related quality of life (HRQOL) (EORTC QLQ-C30)

    The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) Core 30 (EORTC QLQ-C30)

    Time frame: During 18 weeks of the neoadjuvant treatment

  8. Health-related quality of life (HRQOL)

    The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire Breast Cancer (EORTC QLQ- BR23) will be used to measure the HRQOL

    Time frame: During 18 weeks of the neoadjuvant treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Feb 2026, 18 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 18 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 1, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2031
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06340230
Lead sponsor
Shengjing Hospital
Responsible party
Caigang Liu (Director of the Cancer Center, Shengjing Hospital) — Principal investigator
First posted
Apr 1, 2024
Start date
Aug 23, 2024
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2031 (estimated)
Last update
Dec 4, 2024

Study contacts

Nan Niu, MD
Contact
niunannancy@163.com
86-18940256668
Caigang Liu, MD
principal investigator · Shengjing Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Adebrelimab

Start the discussion